@article{41d5acbaea8f4bb18bac0593d40eb825,
title = "Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication",
author = "Jeromie Ballreich and Charles Bennet and Moore, {Thomas J.} and Alexander, {G. Caleb}",
note = "Funding Information: Conflict of Interest Disclosures: Dr Coburn reported other from AstraZeneca Canada Honorarium outside the submitted work. Dr Law reported other from Ipsen Advisory Board Member outside the submitted work. Dr Singh reported personal fees from IPSEN and grants from NOVARTIS/AAA outside the submitted work. Dr Myrehaug reported personal fees from AAA/Novartis and grants from Ipsen during the conduct of the study. Dr Hallet reported personal fees from Ipsen Biopharamceuticals Canada speaker honoraria and personal fees from Advanced Accelerator Applications speaker honoraria during the conduct of the study. No other disclosures were reported.",
year = "2021",
month = nov,
doi = "10.1001/jamaoncol.2021.4757",
language = "English (US)",
volume = "7",
pages = "1720--1721",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "11",
}